Home › NDC Lookup › RxCUI directory › RxCUI 2172491

Doxylamine succinate 10.5 MG / phenylephrine hydrochloride 10 MG Oral Tablet — RxCUI 2172491

RxNorm drug concept · Semantic clinical drug
RxCUI 2172491 Semantic clinical drug · SCD ● Current RxNorm concept 1 FDA product 2 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2172491
Official nameDoxylamine succinate 10.5 MG / phenylephrine hydrochloride 10 MG Oral Tablet
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdoxylamine succinate 10.5 MG / phenylephrine HCl 10 MG Oral Tablet
FDA products mapped1
Package NDCs mapped2
Reported Medicaid activity (SDUD)262 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Phenylephrine: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Yes, it's the same active ingredient, but used in very different ways depending on the form. The nasal spray delivers a tiny amount directly to the nasal lining to temporarily shri...
  • I see phenylephrine in nasal sprays at the pharmacy AND as an IV drug in the hospital — is it really the same medication?
  • You should check with your doctor first. Phenylephrine constricts blood vessels, which can raise blood pressure and put extra strain on the heart — even from a nasal spray. If you...
  • Can I use the nasal spray if I have high blood pressure or heart disease?
📖 Read our full Phenylephrine guide →

🕸️ Concept Web — How Doxylamine succinate 10.5 MG / phenylephrine hyd... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept Doxylamine succinate 10.5 MG / phenylephrine hydrochloride 10 MG Oral Tablet RxCUI 2172491

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 5

    The active substance itself — no strength, form, or brand attached yet.

    • Doxylamine 3642
    • Phenylephrine 8163
    • Doxylamine / phenylephrine 1441830
    • Doxylamine succinate 23665
    • Phenylephrine hydrochloride 8164
  2. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Doxylamine / phenylephrine Oral Tablet 1441829
    • Doxylamine succinate / phenylephrine hydrochloride Oral Tablet 2648223
    • Doxylamine / phenylephrine Oral Product 1441827
    • Doxylamine / phenylephrine Pill 1441828
    • Doxylamine succinate / phenylephrine hydrochloride Oral Product 2659314
    • Doxylamine succinate / phenylephrine hydrochloride Pill 2662652
    • Oral Tablet 317541
    • Oral Product 1151131
    • +1 more in this family
  3. Clinical & branded drugs 2

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

    • Doxylamine succinate 10.5 MG 2172490
    • Phenylephrine hydrochloride 10 MG 996705

Showing up to 8 concepts per family — 15 of 16 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Doxylamine succinate 10.5 MG SCDC · 2172490
  • Phenylephrine hydrochloride 10 MG SCDC · 996705
  • Doxylamine / phenylephrine Oral Tablet SCDF · 1441829
  • Doxylamine succinate / phenylephrine hydrochloride Oral Tablet SCDFP · 2648223
  • Doxylamine / phenylephrine Oral Product SCDG · 1441827
  • Doxylamine / phenylephrine Pill SCDG · 1441828
  • Doxylamine succinate / phenylephrine hydrochloride Oral Product SCDGP · 2659314
  • Doxylamine succinate / phenylephrine hydrochloride Pill SCDGP · 2662652

📦 FDA Products & Package NDCs

1 product · 2 package NDCs
2 package NDCs map to RxCUI 2172491 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
50991-0626-01 100 TABLET in 1 BOTTLE (50991-626-01) Poly Hist Forte Poly Pharmaceuticals, Inc. 2019-06-01
50991-0626-02 12 BLISTER PACK in 1 CARTON (50991-626-02) / 1 TABLET in 1... Poly Hist Forte Poly Pharmaceuticals, Inc. 2019-06-01
Observed labelers: Poly Pharmaceuticals, Inc. (2) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

💲 Pricing (NADAC)

NADAC is CMS's National Average Drug Acquisition Cost — roughly what pharmacies pay to buy the drug. It is an acquisition benchmark, not your copay.
Per ea · median
$0.6639
Range $0.6639–$0.6639 · middle 50% $0.6639–$0.6639 · 1 NDCs
Latest compatible distributions from the CMS NADAC file · dataset watermark 2026-07-10. Prices vary by package and pharmacy; a distribution is shown instead of one misleading number. Rows the dataset is silent on carry no price. No zero-cost conclusion should be drawn.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.